BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 15455376)

  • 1. O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course.
    Watanabe T; Katayama Y; Komine C; Yoshino A; Ogino A; Ohta T; Fukushima T
    Int J Cancer; 2005 Feb; 113(4):581-7. PubMed ID: 15455376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene.
    Nakamura M; Watanabe T; Yonekawa Y; Kleihues P; Ohgaki H
    Carcinogenesis; 2001 Oct; 22(10):1715-9. PubMed ID: 11577014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas.
    Komine C; Watanabe T; Katayama Y; Yoshino A; Yokoyama T; Fukushima T
    Brain Pathol; 2003 Apr; 13(2):176-84. PubMed ID: 12744471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary individualized chemotherapy for malignant astrocytomas based on O6-methylguanine-deoxyribonucleic acid methyltransferase methylation analysis.
    Watanabe T; Katayama Y; Ogino A; Ohta T; Yoshino A; Fukushima T
    Neurol Med Chir (Tokyo); 2006 Aug; 46(8):387-93; discussion 393-4. PubMed ID: 16936459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors.
    Bello MJ; Alonso ME; Amiñoso C; Anselmo NP; Arjona D; Gonzalez-Gomez P; Lopez-Marin I; de Campos JM; Gutierrez M; Isla A; Kusak ME; Lassaletta L; Sarasa JL; Vaquero J; Casartelli C; Rey JA
    Mutat Res; 2004 Oct; 554(1-2):23-32. PubMed ID: 15450401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations.
    Jesien-Lewandowicz E; Jesionek-Kupnicka D; Zawlik I; Szybka M; Kulczycka-Wojdala D; Rieske P; Sieruta M; Jaskolski D; Och W; Skowronski W; Sikorska B; Potemski P; Papierz W; Liberski PP; Kordek R
    Cancer Genet Cytogenet; 2009 Jan; 188(2):77-82. PubMed ID: 19100509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy.
    Kamiryo T; Tada K; Shiraishi S; Shinojima N; Kochi M; Ushio Y
    Neurosurgery; 2004 Feb; 54(2):349-57; discussion 357. PubMed ID: 14744281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study.
    Zawlik I; Vaccarella S; Kita D; Mittelbronn M; Franceschi S; Ohgaki H
    Neuroepidemiology; 2009; 32(1):21-9. PubMed ID: 18997474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
    Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
    PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
    Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP
    Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase.
    Wiencke JK; Aldape K; McMillan A; Wiemels J; Moghadassi M; Miike R; Kelsey KT; Patoka J; Long J; Wrensch M
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1774-83. PubMed ID: 16030116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis.
    Esteller M; Risques RA; Toyota M; Capella G; Moreno V; Peinado MA; Baylin SB; Herman JG
    Cancer Res; 2001 Jun; 61(12):4689-92. PubMed ID: 11406538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
    Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
    Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
    Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
    Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
    Taal W; Dubbink HJ; Zonnenberg CB; Zonnenberg BA; Postma TJ; Gijtenbeek JM; Boogerd W; Groenendijk FH; Kros JM; Kouwenhoven MC; van Marion R; van Heuvel I; van der Holt B; Bromberg JE; Sillevis Smitt PA; Dinjens WN; van den Bent MJ;
    Neuro Oncol; 2011 Feb; 13(2):235-41. PubMed ID: 21177338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors.
    Yin D; Xie D; Hofmann WK; Zhang W; Asotra K; Wong R; Black KL; Koeffler HP
    Mol Carcinog; 2003 Jan; 36(1):23-31. PubMed ID: 12503076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.
    Groenendijk FH; Taal W; Dubbink HJ; Haarloo CR; Kouwenhoven MC; van den Bent MJ; Kros JM; Dinjens WN
    J Neurooncol; 2011 Feb; 101(3):405-17. PubMed ID: 20593220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.
    Brell M; Tortosa A; Verger E; Gil JM; Viñolas N; Villá S; Acebes JJ; Caral L; Pujol T; Ferrer I; Ribalta T; Graus F
    Clin Cancer Res; 2005 Jul; 11(14):5167-74. PubMed ID: 16033832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.